Genezen Secures $18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities
Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO),announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners.